The Nima Sharifi Laboratory is seeking to recruit outstanding postdoctoral associates with a primary interest in the fundamental mechanisms of human biology, biochemistry, metabolism, genetics, or medicinal and analytical chemistry.
These positions present exceptional opportunities to partner with an outstanding clinical urology program in a new institute dedicated to rapidly translating basic discoveries to the clinic.
The overarching goal of the institute’s research program is to define the underlying biochemical and clinical behavior of genitourinary cancers, in order to identify new strategies that will ultimately lead to durable clinical benefits.
The Sharifi laboratory focuses on mechanistic discovery to understand the metabolic and molecular mechanisms of androgen synthesis and other areas of steroid metabolism that lead to resistance to hormonal therapy.
Our work is revealing fundamental endocrine mechanisms in both normal physiology and disease, including stress, aging, and glucocorticoid resistance, with broad applications to oncology and cancer physiology.
More information can be found online () and candidates should submit a CV and summary of their research interests via e-mail to .
Specific research areas include: Metabolic and genetic changes required for hormone therapy resistance in prostate and breast cancers Discovery of entirely new mechanisms of endocrine physiology and regulation Clinical validation in patients and clinical trials using innovative approaches Identifying targets for the development of new pharmacologic therapies Drug discovery for novel therapeutic targets We discovered the first example of a gain-of-function in a steroid-synthesizing enzyme that enables prostate cancer resistance to hormonal therapy (Chang, et al.
Cell.
2013;154:1074-84).
We have shown that our discovery of a gain-of-function in a steroid-synthesizing enzyme is a predictive biomarker of poor outcomes after hormonal therapy (Hearn, et al.
Lancet Oncol.
2016;17:1435-44;
JAMA Oncol.
2018;4:558-62;
JAMA Oncol.
2020;6(4):e196496).
We also discovered that abiraterone works by conversion to a more active steroidal metabolite (Li, et al.
Nature.
2015;523:347-51), that metabolism is pharmacologically modifiable to optimize therapy (Li, et al.
Nature.
2016;533:547-51) and that these events are a class effect of steroidal androgen synthesis inhibitors (Alyamani, et al.
Cell Chem Biol.
2017;24:825-32) and genetic determination of metabolite generation (Alyamani, et al.
J Clin Invest.
2018;128:3333-40).
We reported that blockade of hexose-6-phosphate dehydrogenase normalizes glucocorticoid metabolism and reverses enzalutamide resistance, credentialing a new pharmacologic vulnerability (Li, et al.
Sci Transl Med13;
2021. We also reported that the BMX kinase controls a steroid-synthesizing enzyme that enables treatment resistance, thus indicating potential new treatment vulnerabilities for sex steroid-dependent cancers (Li, et al.
J Clin Invest.
2023;133(2):e163498).
Most recently, we discovered a new pathway of androgen and estrogen biosynthesis from oxysterols that bypasses the p450 enzymes that were thought to be essential for sex steroid biosynthesis, thus identifying new targets for drug development (Zhu, et al.
Nature Commun.
2025).
This position is ideal for an individual with a strong interest in basic mechanistic discoveries, as well as rapid translation of to the bedside.